








Clinical utility of serum holotranscobalamin in the assessment of Vitamin B₁₂ deficiency in patients with Hypothyroidism

Reshma Shridhar¹ , Janice DSA² , Prathima Mangalore Balakrishna^{3*} , Vishnu Nair⁴ , Kiran Kumar⁵ , Sushith⁶ , Suriyan Nair⁷ 

^{1,2,3,6,7}Department of Biochemistry, ⁵Department of Psychiatry, AJ Institute of Medical Sciences and Research Centre, Mangaluru - 575004, Karnataka, India.

⁴IQRAA International Hospital and Research Centre, Kozhikode, Kerala, India.

Keywords

Case-Control Studies
Hypothyroidism
Vitamin B₁₂ Deficiency
Transcobalamins
Thyroid disorder

Abstract

Thyroid disorder is the second most frequently encountered endocrinological condition after diabetes mellitus. When vitamin B₁₂ deficiency coexists with hypothyroidism, neurological symptoms and signs are more pronounced. Holotranscobalamin (Active B₁₂) may be a more sensitive marker in the early diagnosis of Vitamin B₁₂ deficiency than total B₁₂. The study aimed to evaluate the serum levels of active B₁₂ in patients with clinical hypothyroidism and to correlate active B₁₂ and thyroid profiles. The case-control study was carried out in a tertiary hospital on 80 study subjects, comprising 40 confirmed hypothyroidism patients and 40 age- and gender-matched healthy controls. Serum thyroid profile and active B₁₂ assays were performed by Chemiluminescent Microparticle Immunoassay. Statistical methods such as independent t-test and Pearson's correlation were used to compare and correlate quantitative data. A significant percentage (90%) of hypothyroid patients had vitamin B₁₂ deficiency, with a mean value of 17.39 ± 5.73 pmol/L. Active B₁₂ showed a positive correlation with T₃ ($r = 0.818$; $P < 0.001$) and T₄ ($r = 0.851$; $P < 0.001$) and a negative correlation with TSH ($r = -0.930$; $P < 0.001$). Vitamin B₁₂ deficiency was found in patients with hypothyroidism. This vitamin B₁₂ deficiency may be caused by inadequate malabsorption, as seen in hypothyroidism. HoloTC (Active B₁₂) may be a promising marker for early detection and management of B₁₂ deficiency, which may be beneficial in preventing irreversible neurological damage at an early stage.

1 Introduction

The thyroid is an important endocrine gland that releases thyroid hormones (T₃ and T₄), these hormones are involved in the metabolism, growth, and development of the human body. Thyroid hormones are regulated by thyroid-stimulating hormone or thyrotropin (TSH), which is secreted by the anterior pituitary gland. Currently, thyrotropin (TSH), thyroxine (T₄), or T₄ in combination with triiodothyronine (T₃) are suggested to be used as indicators in laboratory testing to clinically evaluate thyroid function [1,2]. Hypothyroidism is defined as low T₄ levels with elevated serum TSH levels. The most common cause of hypothyroidism is iodine deficiency. Hypothyroidism may also occur as a result of radioactive iodine treatment, thyroid surgery, thyroid cancer, after external beam radiotherapy for head and neck malignancy, and certain medications (such as lithium, amiodarone, tyrosine kinase inhibitors, thalidomide,

interferon-alpha, monoclonal antibodies, and antiepileptic drugs) [3].

Vitamin B₁₂ (cobalamin), a water-soluble vitamin, which was originally discovered as an anti-pernicious anemia factor, has two biologically active forms, namely methylcobalamin (MeCbl) and adenosylcobalamin (AdoCbl), AdoCbl also known as coenzyme B₁₂ [4]. Vitamin B₁₂ is essential for the synthesis of myelin, which is required for the formation of the myelin sheath, a protective layer for the spinal, cranial, and peripheral nerves. These functions are explained by the role of vitamin B₁₂ as a cofactor for two enzymes methionine synthase and l-methylmalonyl-CoA mutase. Thus, vitamin B₁₂ acts as a cofactor for the synthesis of methionine by transferring the methyl group to homocysteine (Hcy). Further methionine metabolism to S-adenosyl methionine (SAM) is required for the synthesis of myelin, maintenance of neuronal integrity,

and regulation of neurotransmitters. Vitamin B₁₂ deficiency causes either the incorporation of abnormal fatty acids into myelin sheaths or destruction of myelin sheaths, thus leading to impaired neural function and/or transmissions. This may be the root cause of the neurological symptoms associated with vitamin B₁₂ deficiency [5].

The absorption, blood transport, and cellular uptake of vitamin B₁₂ are dependent upon binding proteins such as haptocorrin (HC), intrinsic factor (IF), transcobalamin (TC), and cell surface receptors [6]. In serum, vitamin B₁₂ is transported via two distinct binding proteins TC and HC. When vitamin B₁₂ binds to TC and HC, the resulting complexes are known as holo-transcobalamin (HoloTC or Active B₁₂), and holohaptocorrin (HoloHC - inactive form of vitamin B₁₂). The major fraction of circulating vitamin B₁₂ (70-90%) is bound to HC. The actual function of this HC-bound vitamin B₁₂ is unknown, but it is believed to be biologically unavailable to most cells. HoloTC binds the remaining 10–30% of vitamin B₁₂ [7].

Vitamin B₁₂ deficiency has been commonly reported in patients with thyroid disorders, especially in autoimmune thyroid diseases such as Hashimoto's. This association is probably due to impaired vitamin B₁₂ absorption by atrophic gastritis and/or pernicious anemia associated with autoimmune thyroid disease [8]. Other causes of vitamin B₁₂ deficiency in hypothyroid patients include inadequate dietary intake, altered intestinal absorption due to sluggish bowel motility, bowel wall oedema, and bacterial overgrowth. Non-autoimmune causes of B₁₂ deficiency in hypothyroid patients have not been thoroughly investigated, and they may differ depending on dietary habits in different populations. Symptoms such as weakness, diarrhea, numbness, abdominal pain, paresthesia, memory loss, dizziness, dysphagia, and depression have been reported in hypothyroid patients. Patients with both hypothyroidism and vitamin B₁₂ deficiency also have similar symptoms. Dysphagia, numbness, and paresthesia were the most commonly reported symptoms in hypothyroid patients with vitamin B₁₂ deficiency [9].

Vitamin B₁₂ deficiency has traditionally been diagnosed by measuring total serum vitamin B₁₂ levels. The limitation of this biomarker is that it assesses total circulating vitamin B₁₂, of which 70–90% is bound to haptocorrin, which is not available to the cells and is unreliable to reflect cellular vitamin B₁₂ status. According to the findings of studies on serum and cellular vitamin B₁₂ levels, serum B₁₂ levels do not always correspond to cellular B₁₂ status. HoloTC is advantageous in determining vitamin B₁₂ status as it reflects the metabolically active fraction of vitamin B₁₂ in the serum [10]. Thus decreased concentrations of holoTC may be the earliest and most sensitive marker of vitamin B₁₂ deficiency [11]. The present study was conducted to determine the clinical utility of serum holo-transcobalamin (active B₁₂) in assessing vitamin B₁₂ deficiency in hypothyroid patients and to correlate active B₁₂ and thyroid profiles.

2 Materials and Methods

2.1 Study Duration and Setting

A prospective case-control study was carried out for a period of 6 months (December 2018 to May 2019) at a tertiary care hospital in Mangaluru, Karnataka, India. Ethical clearance was obtained from the Institutional Ethics Committee (AJEC/REV/70/2018).

2.2 Study Population

The current case-control study included 80 subjects, comprising 40 confirmed hypothyroidism patients (5 males and 35 females) (mean age: 34.58 ± 8.37) and 40 age- and gender-matched healthy controls (5 males and 35 females) (mean age: 33.28 ± 10.25). Written informed consent was obtained from all participants in the study. Patients with a history of kidney disease, diabetes mellitus, cardiac disease and liver disease, hypertension, pregnancy, and multivitamin supplementation were excluded from the study.

2.3 Sample Size

The sample size was estimated using the OpenEpi, version 3 (www.openepi.com). The sample size was calculated using the mean and standard deviation of vitamin B₁₂ levels in hypothyroidism reported earlier by Khubchandani *et al.*, [12]. The estimated sample size was 40 subjects in each group (a total of 80 subjects), with a confidence interval (CI) of 95%, power of 80%, and a case-control ratio of 1:1.

2.4 Sample collection and processing

Blood samples were collected after overnight fasting. 5 ml venous blood was collected from each study subject. These blood samples were allowed to stand at room temperature for clot formation before being centrifuged for 10 minutes at approximately 3500 rpm. Measurements of serum concentrations of Total T₃, Total T₄, TSH, and Vitamin B₁₂ were done using Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of holo-transcobalamin (active B₁₂) in serum on the ARCHITECT iSystem (Abbott Diagnostics, Abbott Park, IL, USA). According to the applied reagent kit, the reference range for active B₁₂ is considered to be 25.1 - 165.0 pmol/L.

2.5 Statistical Analysis

Statistical analysis was performed using IBM SPSS version 20.0 (SPSS, Inc., Chicago, IL, USA). Categorical variables were represented by frequency and percentage and continuous data were expressed as mean \pm standard deviation (SD). A Chi-square test was performed to determine the association between categorical variables. An independent t-test can be used to compare means between cases and controls. Pearson correlation analysis was performed to analyze the association between age, thyroid hormones, and active B₁₂. $P < 0.05$ was considered statistically significant.

3 Results

The present study comprised 80 subjects, of which 40 were cases (5 males and 35 females) (mean age: 34.58 ± 8.37) and 40 were age- and gender-matched healthy controls (5 males and 35 females) (mean age: 33.28 ± 10.25). The demographic and biochemical parameters of the study subjects are shown in Table 1. According to the normal reference range, the cut-off for vitamin B₁₂ deficiency based on HoloTC was considered at < 25 pmol/L.

The distribution of study subjects based on active vitamin B₁₂ status is shown in Fig. 1. Symptoms of numbness, paresthesia, and dysphagia were seen in B₁₂ deficient patients compared to B₁₂ sufficient patients.




Fig. 1: Distribution of study subjects based on active Vitamin B₁₂ status.

We obtained a significant decrease in serum T₃ level (0.60 ± 0.17 nmol/L; $P < 0.001$), a significantly decreased serum T₄ level (3.66 ± 0.85 µg/dL; $P < 0.001$) and a significantly increased TSH level (59.38 ± 8.09 mIU/L; $P < 0.001$) in patients with hypothyroidism as compared to controls. Patients with hypothyroidism had significantly lower serum vitamin B₁₂ levels (17.39 ± 5.73 pmol/L; $P < 0.001$) as compared to controls (55.09 ± 7.69 pmol/L; $P < 0.001$). A significant percentage (90%) of hypothyroid patients had vitamin B₁₂ deficiency, as shown by active B₁₂ levels (Table 1).

Correlation of active B₁₂ with age and thyroid profile is shown in Table 2. Active B₁₂ shows a positive correlation with T₃ ($r = 0.818$; $P < 0.001$) and T₄ ($r = 0.851$; $P < 0.001$) (Fig. 2 & 3). There was a negative correlation between Active B₁₂ and TSH ($r = -0.930$; $P < 0.001$) (Fig. 4).

The results showed that there was no significant correlation ($r = -0.140$; $P = 0.217$) found between age and thyroid profile / active B₁₂.




Fig. 2: Correlation between T₃ and Active B₁₂.




Fig. 3: Correlation between T₄ and Active B₁₂.




Fig 4: Correlation between TSH and Active B₁₂.

Table 1: Demographic and biochemical parameters of the study subjects.

Parameters	Cases (n = 40)	Controls (n = 40)	P value
	N (%) / Mean ± SD (Min. – Max.)		
Age (in years)	34.58 ± 8.37 (19.00 – 49.00)	33.28 ± 10.25 (18.00 – 49.00)	0.536
Age group			
18 – 26 years	9 (22.50)	14 (35.00)	0.466
27 – 35 years	12 (30.00)	10 (25.00)	
> 35 years	19 (47.50)	16 (40.00)	
Gender			
Males	5 (12.50)	5 (12.50)	1.000
Females	35 (87.50)	35 (87.50)	
Hormones			
Serum T ₃ (nmol/L)	0.60 ± 0.17 (0.27 – 0.93)	1.29 ± 0.20 (0.98 – 1.74)	< 0.001
Serum T ₄ (µg/dL)	3.66 ± 0.85 (1.49 – 4.69)	8.01 ± 1.22 (5.35 – 10.89)	< 0.001
Serum TSH (mIU/L)	59.38 ± 8.09 (43.60 – 76.60)	1.99 ± 1.45 (0.47 – 6.43)	< 0.001
Serum Vitamin B ₁₂ (pmol/L)	17.39 ± 5.73 (6.80 – 34.87)	55.09 ± 7.69 (38.09 – 69.78)	< 0.001

Table 2: Correlation between age, thyroid profile and active B₁₂.

		Correlations				
		Age	T ₃	T ₄	TSH	B ₁₂
Age	Pearson Correlation	1	-0.076	-0.077	0.103	-0.140
	Sig. (2-tailed)		0.500	0.497	0.361	0.217
	N	80	80	80	80	80
T ₃	Pearson Correlation	-0.076	1	0.854**	-0.878**	0.818**
	Sig. (2-tailed)	0.500		0.000	0.000	0.000
	N	80	80	80	80	80
T ₄	Pearson Correlation	-0.077	0.854**	1	-0.905**	0.851**
	Sig. (2-tailed)	0.497	0.000		0.000	0.000
	N	80	80	80	80	80
TSH	Pearson Correlation	0.103	-0.878**	-0.905**	1	-0.930**
	Sig. (2-tailed)	0.361	0.000	0.000		0.000
	N	80	80	80	80	80
B ₁₂	Pearson Correlation	-0.140	0.818**	0.851**	-0.930**	1
	Sig. (2-tailed)	0.217	0.000	0.000	0.000	
	N	80	80	80	80	80

** Correlation is significant at the 0.01 level (2-tailed).

4 Discussion

Hypothyroidism (underactive thyroid) is defined as the failure of the thyroid gland to produce enough thyroid hormones (T₃ and T₄) needed for the body's metabolic demands. Untreated hypothyroidism can lead to cognitive impairment, hypertension, dyslipidemia, infertility, and neuromuscular dysfunction [13]. The prevalence of vitamin B₁₂ deficiency in both hypothyroidism and autoimmune thyroid disease (AITD) reflects the nutritional status of the population. AITD can be independently associated with pernicious anemia and atrophic gastritis, which may lead to impaired absorption of vitamin B₁₂ [14]. An immune response against the gastric H/K-ATPase in the parietal cells of the stomach occurs in an autoimmune disorder [15]. According to Centanni *et al.*, (1999), in patients with AITD, atrophic gastritis was found in 22 cases (35%), with pernicious anemia in 10 cases (16%), and also indicated that about one-third of AITD patients have atrophic gastritis [16]. Intrinsic factor antibodies have also been found in AITD patients [17]. In the absence of AITD, the association between hypothyroidism and vitamin B₁₂ deficiency has not been thoroughly evaluated. This association may

differ depending on dietary habits among different population groups [9]. Direct biomarkers such as total B₁₂ and holo-transcobalamin (holoTC) and the two metabolic markers homocysteine (Hcy) and methylmalonic acid (MMA) are preferred for diagnosing B₁₂ deficiency [18]. In our study, total B₁₂, homocysteine, and MMA were not studied.

The physiology of vitamin B₁₂ suggested that holoTC may be a sensitive marker of early vitamin B₁₂ deficiency. Currently, there are 3 methods for analyzing holoTC: direct measurement of the complex between transcobalamin and vitamin B₁₂, measurement of the amount of transcobalamin saturated with vitamin B₁₂ or measurement of vitamin B₁₂ attached to transcobalamin [19]. In clinical studies, the holoTC performs better than total vitamin B₁₂ in assessing B₁₂ deficiency based on the high concentration of methylmalonic acid [19] and red cell cobalamin concentrations [20]. In renal disease, plasma holoTC is increased. Therefore, holoTC cannot be used as an indicator of vitamin B₁₂ status in patients with renal disease [21].

In our study, we obtained a significant decrease in serum T₃ level, a significantly decreased serum T₄ level, and a significantly increased TSH level in patients with

hypothyroidism as compared to controls. Li *et al.*, (2014) also found a significant decrease in the serum T₃ levels (1.02 ± 0.984 nmol/L), a significant decrease in T₄ levels (34.66 ± 13.201 nmol/L), and a significantly increased TSH level (21.99 ± 24.418 mIU/L) in cases, which was consistent with our findings [22].

In the present study, patients with hypothyroidism had significantly lower serum vitamin B₁₂ levels as compared to controls. A significant percentage (90%) of hypothyroid patients had vitamin B₁₂ deficiency, as shown by active B₁₂ levels. Similar findings were reported by Khubchandani *et al.*, (2015) who found that, serum vitamin B₁₂ levels ($P < 0.05$) of hypothyroidism patients are significantly lower (187.38 ± 35.89) than normal subjects (365.17 ± 45.82). The prevalence of B₁₂ deficiency was observed in hypothyroid patients and 32 out of 50 (64%) patients were found to have B₁₂ deficient [12]. Lakho *et al.*, (2018) studied the prevalence of B₁₂ deficiency in hypothyroid patients and found that 105 (72%) of 145 patients had low B₁₂ levels [23]. Similarly, Jabbar *et al.*, (2008) reported the prevalence of B₁₂ deficiency in hypothyroid patients and found that 47 (40.5%) of 116 patients had low B₁₂ levels [9].

Vitamin B₁₂ deficiency is a common condition with non-specific clinical symptoms. Manifestations of vitamin B₁₂ deficiency range from subtle, nonspecific clinical features to severe neurological and neuropsychiatric complications [24]. The metabolic level at which a vitamin B₁₂ deficiency should be classified varies depending on the method and laboratory [25]. The prevalence of vitamin B₁₂ deficiency may be underestimated because people with diets rich in B₁₂ may have food-cobalamin malabsorption issues due to atrophic gastritis and as a result of *Helicobacter pylori* infection [26].

In our study, Active B₁₂ showed a positive correlation with T₃ and T₄. There was a negative correlation between Active B₁₂ and TSH and there was no significant correlation between age and thyroid profile / Active B₁₂. According to a study conducted by Ranjan *et al.*, (2020) vitamin B₁₂ has a positive correlation with serum T₃ ($r = 0.01$; $P = 0.94$) and T₄ ($r = 0.05$; $P = 0.77$) [27]. In another study, there was no correlation found between TSH and vitamin B₁₂ ($r = 0.006$; $P = 0.935$) [28]. A recent study found no correlation between vitamin B₁₂ with age and thyroid profile [17].

The present study revealed that HoloTC showed better diagnostic accuracy than vitamin B₁₂ and can be used as a primary screening test in patients suspected of vitamin B₁₂ deficiency. It is recommended that patients with autoimmune thyroid diseases should be periodically screened for vitamin B₁₂ deficiency.

5 Conclusion

Vitamin B₁₂ deficiency was observed in patients with hypothyroidism. Active B₁₂ (HoloTC) may be a promising marker for the early detection and

management of B₁₂ deficiency, thus proving beneficial in preventing irreversible neurological damage at the earliest. To prevent complications associated with B₁₂ deficiency, studies in different clinical settings are required to clarify the efficacy of HoloTC in determining vitamin B₁₂ status and to establish a causal relationship between active B₁₂ and hypothyroidism. In addition, further research is needed to compare total B₁₂ and active B₁₂ in hypothyroid patients to identify which of the two is a sensitive marker of vitamin B₁₂ deficiency.

Conflicts of Interest

The author declares that there is no conflict of interest.

References

- Menjo, M., Yamaguchi, S., Murata, Y., Hayashi, Y., Nagaya, T., Ohmori, S., Refetoff, S. & Seo, H. (1999). Responsiveness to thyroid hormone is enhanced in rat hepatocytes cultured as spheroids compared with that in monolayers: altered responsiveness to thyroid hormone possibly involves complex formed on thyroid hormone response elements. *Thyroid*, 9(9): 959–967. <https://doi.org/10.1089/thy.1999.9.959>.
- Pearce, E.N., Hennessey, J.V. & McDermott, M.T. (2011). New American Thyroid Association and American Association of Clinical Endocrinologists guidelines for thyrotoxicosis and other forms of hyperthyroidism: significant progress for the clinician and a guide to future research. *Thyroid*, 21(6): 573–576. <https://doi.org/10.1089/thy.2011.0104>.
- Garber, J.R., Cobin, R.H., Gharib, H., Hennessey, J.V., Klein, I., Mechanick, J.I., Pessah-Pollack, R., Singer, P.A. & Woeber, K.A. (2012). Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Thyroid*, 22(12): 1200–1235. <https://doi.org/10.1089/thy.2012.0205>.
- Watanabe, F. (2007). Vitamin B12 sources and bioavailability. *Exp. Biol. Med.*, 232(10): 1266–1274. <https://doi.org/10.3181/0703-MR-67>.
- Ammouri, W., Harmouche, H., Khibri, H., Benkirane, S., Azlarab, M., Mouatassim, N., Maamar, M., Mezalek Tazi, Z. & Adnaoui, M. (2019). Neurological Manifestations of Cobalamin Deficiency. *Open Access J. Neurol. Neurosurg.*, 12(2): 555834. <https://doi.org/10.19080/OAJNN.2019.12.555834>.
- Surendran, S., Adaikalakoteswari, A., Saravanan, P., Shatwaan, I.A., Lovegrove, J.A. & Vimalaswaran, K.S. (2018). An update on vitamin B12-related gene polymorphisms and B12 status. *Genes Nutr.*, 13(1): 1–35. <https://doi.org/10.1186/s12263-018-0591-9>.
- Brady, J., Wilson, L., McGregor, L., Valente, E. & Orning, L. (2008). Active B12: a rapid, automated

- assay for holotranscobalamin on the Abbott AxSYM analyzer. *Clin. Chem.*, 54(3): 567–573. <https://doi.org/10.1373/clinchem.2007.096784>.
- [8]. Aktaş, H.Ş. (2020). Vitamin B12 and Vitamin D levels in patients with Autoimmune Hypothyroidism and their correlation with Anti-Thyroid Peroxidase Antibodies. *Med. Princ. Pract.*, 29(4): 364–370. <https://doi.org/10.1159/000505094>.
- [9]. Jabbar, A., Yawar, A., Waseem, S., Islam, N., Ul Haque, N., Zuberi, L., Khan, A. & Akhter, J. (2008). Vitamin B12 deficiency common in primary hypothyroidism. *J. Pak. Med. Assoc.*, 58(5): 258–261.
- [10]. Hannibal, L., Lysne, V., Bjørke-Monsen, A.L., Behringer, S., Grünert, S.C., Spiekerkoetter, U., Jacobsen, D.W. & Blom, H.J. (2016). Biomarkers and Algorithms for the Diagnosis of Vitamin B₁₂ Deficiency. *Front. Mol. Biosci.*, 3: 27. <https://doi.org/10.3389/fmolb.2016.00027>.
- [11]. Refsum, H. & Smith, A.D. (2003). Low vitamin B-12 status in confirmed Alzheimer's disease as revealed by serum holotranscobalamin. *J. Neurol. Neurosurg. Psychiatry*, 74(7): 959–961. <http://dx.doi.org/10.1136/jnnp.74.7.959>.
- [12]. Khubchandani, A., Parmar, V., Shah, P. & Malek, R. (2015). Vitamin B12 deficiency common in primary hypothyroidism. *Int. J. Res. Med.*, 4(4): 158-160.
- [13]. Gaitonde, D.Y., Rowley, K.D. & Sweeney, L.B. (2012). Hypothyroidism: An Update. *Am. Fam. Physician*, 86(3): 244–251.
- [14]. Collins, A.B. & Pawlak, R. (2016). Prevalence of vitamin B-12 deficiency among patients with thyroid dysfunction. *Asia Pac. J. Clin. Nutr.*, 25(2): 221–226. <https://doi.org/10.6133/apjcn.2016.25.2.22>.
- [15]. De Oleo, I.E.R., Saldarriaga, M.M., Silverman, M., Thibaud, S. & Sponholz, L.R. (2017). Polyglandular Autoimmune Syndrome Type IIIB: Hyperthyroidism and Pernicious Anemia, a Reminder of the Past. *J. Endocrinol. Metab.*, 7(5): 159–161. <https://doi.org/10.14740/jem451w>.
- [16]. Centanni, M., Marignani, M., Gargano, L., Corleto, V.D., Casini, A., Delle Fave, G., Andreoli, M. & Annibale, B. (1999). Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. *Arch. Intern. Med.*, 159(15): 1726–1730. <https://doi.org/10.1001/archinte.159.15.1726>.
- [17]. Jaya Kumari, S., Bantwal, G., Devanath, A., Aiyar, V. & Patil, M. (2015). Evaluation of serum vitamin B12 levels and its correlation with anti-thyroperoxidase antibody in patients with autoimmune thyroid disorders. *Indian J. Clin. Biochem.*, 30(2): 217–220. <https://doi.org/10.1007/s12291-014-0418-4>.
- [18]. Campos, A.J., Risch, L., Nydegger, U., Wiesner, J., Vazquez Van Dyck, M., Renz, H., Stanga, Z. & Risch, M. (2020). Diagnostic Accuracy of Holotranscobalamin, Vitamin B12, Methylmalonic Acid, and Homocysteine in Detecting B12 Deficiency in a Large, Mixed Patient Population. *Dis. Markers*, 2020: 7468506. <https://doi.org/10.1155/2020/7468506>.
- [19]. Nexo, E. & Hoffmann-Lücke, E. (2011). Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility. *Am. J. Clin. Nutr.*, 94(1): 359S–365S. <https://doi.org/10.3945/ajcn.111.013458>.
- [20]. Valente, E., Scott, J.M., Ueland, P.M., Cunningham, C., Casey, M. & Molloy, A.M. (2011). Diagnostic accuracy of holotranscobalamin, methylmalonic acid, serum cobalamin, and other indicators of tissue vitamin B₁₂ status in the elderly. *Clin. Chem.*, 57(6): 856–863. <https://doi.org/10.1373/clinchem.2010.158154>.
- [21]. Herrmann, W. & Obeid, R. (2008). Causes and early diagnosis of vitamin B12 deficiency. *Dtsch. Arztebl. Int.*, 105(40): 680–685. <https://doi.org/10.3238/arztebl.2008.0680>.
- [22]. Li, H., Yuan, X., Liu, L., Zhou, J., Li, C., Yang, P., Bu, L., Zhang, M. & Qu, S. (2014). Clinical evaluation of various thyroid hormones on thyroid function. *Int. J. Endocrinol.*, 2014: 618572. <https://doi.org/10.1155/2014/618572>.
- [23]. Lakho, A.S., Channa, A.A., Dars, A.G., Shah, S.Z.A. & Iqbal, M. (2018). Vitamin B12 Deficiency: Vitamin B12 Deficiency in Patients with Hypothyroidism. *Professional Med. J.*, 25: 753–758. <https://doi.org/10.29309/TPMJ/2018.25.05.321>.
- [24]. Chan, C.Q., Low, L.L. & Lee, K.H. (2016). Oral Vitamin B12 Replacement for the Treatment of Pernicious Anemia. *Front. Med.*, 3: 38. <https://doi.org/10.3389/fmed.2016.00038>.
- [25]. Carmel, R. (2014). Cobalamin (vitamin B12). In: Ross, A.C., Caballero, B.H., Cousins, R.J., Tucker, K.L. & Ziegler, T.R. (2012). *Modern nutrition in health and disease*, 11th ed., Baltimore, MD: Lippincott Williams & Wilkins, pp. 369-389.
- [26]. Allen, L.H. (2008). Causes of vitamin B12 and folate deficiency. *Food Nutr. Bull.*, 29: S20–S37. <https://doi.org/10.1177/15648265080292S105>.
- [27]. Ranjan, A., Sudha, K., Nandini, M. & Durgarao, Y. (2020). Novel evidence of relationship between serum vitamin B₁₂ and folate with total vitamin D in subclinical hypothyroidism. *Biomedicine*, 40(3): 278–280. <https://doi.org/10.51248/v40i3.7>.
- [28]. Tripathi, P., Saxena, N., Verma, M.K. & Singh, A.N. (2019). Association of Vitamin B12, Folate and Ferritin with Thyroid Hormones in Hypothyroidism. *Ann. Int. Med. Den. Res.*, 5(1): BC01-BC06.